Multiple myeloma develops from abnormal plasma cells, the immune cells responsible for producing antibodies. These cancerous cells accumulate in the bone marrow and release large quantities of immunoglobulins, placing exceptional demands on their protein-production machinery. They must continuously fold, transport and maintain vast numbers of proteins while coping with oxidative stress, metabolic pressure and damage to cellular components. Autophagy, a regulated recycling process, helps cells endure these conditions. During autophagy, portions of the cytoplasm, damaged proteins and defective organelles are enclosed in double-membrane structures called autophagosomes. These structures then fuse with lysosomes, where their contents are broken down and recycled.

The new research focuses on ULK3, a member of the Unc-51-like kinase family. Kinases are enzymes that control other proteins by adding phosphate groups to them, thereby changing their activity, location or stability. ULK proteins are widely recognized as early regulators of autophagy, helping cells decide when to initiate the formation of autophagosomes. ULK1 and ULK2 have traditionally received most of the attention in this pathway, while ULK3 has remained less clearly defined. The study now links ULK3 to the biology of multiple myeloma, suggesting that this kinase is not merely a redundant relative of other autophagy regulators but may perform a meaningful function in malignant plasma cells.

The importance of this connection lies in the way myeloma cells use autophagy as a survival strategy. Autophagy is not automatically beneficial or harmful; its effect depends on the cell and its circumstances. In healthy tissues, it can remove damaged mitochondria, eliminate toxic protein aggregates and preserve energy during starvation. In cancer, the same recycling system can help tumor cells tolerate chemotherapy, nutrient deprivation and rapid growth. For plasma-cell cancers, which are burdened by intense protein synthesis, autophagy may be especially valuable because it helps maintain internal quality control and supplies metabolic building blocks when external resources are limited.

According to the study, ULK3 contributes to the ability of multiple myeloma cells to sustain autophagy and remain viable. This finding implies that ULK3 may help coordinate the early steps of the autophagic response or support the broader cellular machinery required to complete it. When such a regulatory node is weakened, cancer cells may lose their capacity to clear damaged material and respond to stress. The result can be an accumulation of defective proteins, impaired organelle function and increased susceptibility to cell death. In myeloma, where the production of abnormal or excessive proteins is already a central feature of the disease, disruption of this balance could be particularly damaging.

The work also offers a biological explanation for why targeting autophagy may affect myeloma survival. Blocking the pathway can produce a form of “stress overload”: cellular waste accumulates, energy production becomes less efficient and damaged components remain in the cytoplasm. At the same time, cancer cells may be unable to reduce their protein burden or adapt to hostile conditions. ULK3 therefore represents a potential control point before the later stages of autophagosome formation and lysosomal degradation. Targeting an early regulator could, in principle, interrupt the process before malignant cells can activate several downstream protective mechanisms.

However, the study does not imply that ULK3 is a universal cancer switch or that a single intervention will eliminate multiple myeloma. Autophagy is a complex network with overlapping regulators, feedback loops and cell-specific effects. If one ULK family member is inhibited, cancer cells may compensate through alternative signaling routes, including pathways controlled by ULK1, ULK2, nutrient-sensing complexes or stress-responsive kinases. The therapeutic challenge will be to determine whether ULK3 can be blocked selectively enough to harm myeloma cells without causing unacceptable injury to normal tissues that also depend on autophagy for long-term maintenance.

The findings are especially relevant to the search for treatments that can overcome drug resistance. Modern myeloma therapy commonly combines agents that attack different aspects of plasma-cell biology, yet many patients eventually relapse because residual malignant cells adapt and survive. A therapy directed at ULK3 could potentially be evaluated alongside established treatments, with the goal of preventing cancer cells from using autophagy as a backup survival program. Such combinations would require careful testing, because some drugs may increase cellular stress and thereby make autophagy inhibition more powerful, while others could trigger compensatory responses that reduce its effect.

Before ULK3 can become a clinical target, researchers will need to clarify how its activity is controlled, which molecular partners it engages and whether its dependence is strongest in particular genetic or metabolic subtypes of myeloma. Biomarkers will also be essential. Measuring ULK3 abundance or activity alone may not predict response if the pathway is governed by several interacting proteins. Investigators may instead need to examine autophagic flux—the rate at which cellular material moves through the pathway—along with protein-folding stress, mitochondrial condition and the molecular features of each patient’s tumor. The study’s central message is therefore both mechanistic and practical: ULK3 helps myeloma cells survive, and understanding that dependence could reveal a new route for weakening a disease that remains difficult to cure.

Subject of Research: Unc-51-like kinase 3 (ULK3), autophagy, cell survival and multiple myeloma

Article Title: Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma

Article References: Tauro, M., Li, T., Sudalagunta, P.R. et al. “Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76711-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76711-0

Keywords: ULK3, autophagy, multiple myeloma, plasma cells, cancer cell survival, cellular stress, kinase signaling, therapeutic targets

Non-small cell lung cancer represents the majority of lung cancer cases, notorious for its high metastatic potential and poor prognosis. Despite therapeutic advances, the underlying cellular behavior enabling tumor cells to migrate and invade under stress remains an enigma. Tumor microenvironments often become hostile due to scarce nutrients, yet cancer cells show a remarkable ability to adapt and survive, contributing to disease progression. This latest research illuminates how NSCLC cells harness autophagy—a self-digestion process—to power their migration during such hostile conditions.

Central to this adaptive response is NDR2 (Nuclear Dbf2-related kinase 2), identified as a master regulator supporting autophagosome formation. Autophagosomes are double-membrane vesicles that encapsulate intracellular components for degradation, essential for cellular homeostasis and survival during nutrient limitations. The precise regulatory mechanisms behind autophagosome biogenesis in migrating cancer cells have remained elusive until now. The research uncovers NDR2’s direct involvement in orchestrating key molecular players of this pathway.

LC3 (Microtubule-associated protein 1 light chain 3), a hallmark of autophagosomes, must be conjugated to autophagic membranes to drive vesicle elongation, a critical step in autophagy. ATG9A, another pivotal autophagy-related protein, traffics membrane sources necessary for autophagosome expansion. This study demonstrates that NDR2 positively regulates the levels and functional activity of both LC3 and ATG9A, ensuring efficient autophagosome formation under starvation stress. These findings intricately link kinase signaling with membrane dynamics in NSCLC cells.

Through a combination of molecular and cellular assays, the authors detail how knocking down NDR2 expression severely impairs LC3 lipidation and ATG9A trafficking, leading to defective autophagosome biogenesis. Without functional autophagy, NSCLC cells exhibit reduced motility and compromised capacity to migrate in nutrient-poor conditions. This phenotype highlights autophagy’s essential role as a facilitator rather than a mere survival mechanism, actively promoting cell migration during metastasis.

The study further explores the spatiotemporal coordination of NDR2 activity, revealing its localization alongside autophagy initiation sites within the cell. This strategic positioning enables NDR2 to fine-tune autophagic flux precisely where membrane nucleation and elongation occur. Such spatial regulation underscores the signaling complexity that tumor cells exploit to adapt swiftly to environmental challenges, thus sustaining aggressive phenotypes.

Importantly, this research elucidates how metabolic stress imposed by starvation paradoxically enhances cancer cell invasiveness via autophagy upregulation. By fueling autophagosome biogenesis, NDR2 enables NSCLC cells not only to maintain energy homeostasis but also to remodel their cytoskeleton and adhesion machinery for efficient migration. This dual role underscores autophagy’s multifaceted contribution beyond recycling cellular components, positioning it as a key driver of metastasis.

The findings propel forward the notion that disrupting NDR2-dependent autophagy pathways could represent a viable therapeutic strategy. Targeting the molecular crosstalk between NDR2, LC3, and ATG9A may disable cancer cell adaptation under nutrient stress, effectively curtailing metastasis. Given that autophagy inhibitors are already being tested in clinical settings, understanding this nuanced regulation offers a refined approach to sensitize tumors to existing therapies.

Moreover, these discoveries prompt a broader reevaluation of autophagy’s role in cancer biology. While traditionally viewed as a cytoprotective mechanism, its direct involvement in enabling cell migration highlights a complex interplay that may vary across tumor types and environmental contexts. This paradigm shift advocates for more targeted research exploring autophagic regulators like NDR2 as multifunctional oncogenic mediators.

This study also raises compelling questions about the potential involvement of NDR2 in other cancers where autophagy and migration intersect under metabolic stress. Expanding this research could reveal conserved signaling pathways exploitable for broader cancer treatment strategies. Additionally, investigating how NDR2-mediated autophagy interfaces with other tumor microenvironment factors such as hypoxia, immune evasion, and extracellular matrix remodeling remains an exciting frontier.

In summary, the research articulated by Biojout et al. reveals that NDR2 acts as a linchpin in NSCLC cell migration under starvation by orchestrating autophagosome biogenesis through LC3 and ATG9A regulation. This mechanistic insight significantly advances our grasp of metastatic processes in nutrient-deprived tumor environments. Therapeutically, targeting NDR2 and its autophagic circuit holds substantial promise in hindering NSCLC progression and improving patient outcomes.

The study’s in-depth molecular analyses combined with functional assays produce a robust framework for future drug development aimed at autophagy regulation. As cancer metastasis continues to be a formidable obstacle, understanding and exploiting vulnerabilities like the NDR2-autophagy axis may revolutionize interventions and save countless lives globally. This transformative research exemplifies the power of integrative biology to decode complex cancer behaviors.

As the scientific community absorbs these findings, the challenge moving forward will be translating this knowledge into clinically effective therapies. Focused efforts on drug discovery targeting kinases like NDR2 and autophagy machinery, alongside patient stratification based on autophagic profiles, will be critical. The convergence of molecular biology and therapeutic innovation marks an exhilarating new chapter in lung cancer research driven by this pivotal study.

In the relentless quest to outsmart cancer’s adaptability, unraveling the molecular circuitry that supports cell migration under metabolic duress is a decisive breakthrough. NDR2’s central role in regulating autophagy to fuel NSCLC invasion highlights novel vulnerabilities in tumor cell survival strategies. This knowledge not only enriches our understanding of cell biology but ignites hope for more effective treatments targeting the dynamic tumor microenvironment.

By elucidating how cancer cells co-opt autophagy machinery to overcome starvation and migrate, this research bridges fundamental molecular insights with clinical imperatives. It sets the stage for a new generation of anticancer approaches aiming at the intersection of metabolism, signaling, and cellular trafficking. The implications of these discoveries will undoubtedly ripple through cancer biology and therapy, galvanizing further innovations.

As researchers continue to unravel the complex networks governing tumor cell behavior, the role of kinases like NDR2 in modulating autophagy emerges as an exciting frontier. This study catalyzes fresh perspectives on targeting metabolic stress responses in cancer, emphasizing the nuanced interplay between survival pathways and metastatic potential. Altogether, these insights herald transformative possibilities in combating one of humanity’s deadliest diseases.

Subject of Research: Regulation of non-small cell lung cancer cell migration under starvation conditions through autophagosome biogenesis mediated by NDR2, LC3, and ATG9A.

Article Title: NDR2 regulates non-small cell lung cancer cell migration under starvation by supporting autophagosome biogenesis through LC3 and ATG9A regulation.

Article References:
Biojout, T., Bergot, E., Taylor, J. et al. NDR2 regulates non-small cell lung cancer cell migration under starvation by supporting autophagosome biogenesis through LC3 and ATG9A regulation. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02889-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02889-9